Hiteck(SZ:300683) Xin Lang Zheng Quan·2025-11-03 01:57Core Viewpoint - Hite Bio's stock has shown significant volatility, with a year-to-date increase of 48.25%, but a notable decline of 40.98% over the past 60 days, indicating potential market fluctuations and investor sentiment shifts [1][2]. Group 1: Stock Performance - As of November 3, Hite Bio's stock price reached 35.15 CNY per share, with a trading volume of 1.36 billion CNY and a market capitalization of 4.601 billion CNY [1]. - The stock has experienced a 7.20% increase over the last five trading days and a 3.08% increase over the last 20 days [1]. - The company has appeared on the "龙虎榜" (a stock market leaderboard) twice this year, with the most recent appearance on July 23 [1]. Group 2: Financial Performance - For the period from January to September 2025, Hite Bio reported a revenue of 422 million CNY, reflecting a year-on-year decrease of 6.45% [2]. - The net profit attributable to the parent company was -158 million CNY, marking a significant year-on-year decline of 297.78% [2]. Group 3: Business Overview - Hite Bio, established on April 8, 1992, and listed on August 8, 2017, is located in Wuhan Economic and Technological Development Zone and specializes in the research, production, and sales of innovative biopharmaceuticals [1]. - The company's revenue composition includes 57.20% from technical services, 25.59% from injectable mouse nerve growth factor, and 17.04% from injectable Epoetin [1]. Group 4: Shareholder Information - As of September 30, Hite Bio had 16,400 shareholders, an increase of 3.47% from the previous period, with an average of 7,426 circulating shares per shareholder, a decrease of 3.35% [2]. Group 5: Dividend Information - Since its A-share listing, Hite Bio has distributed a total of 85.2306 million CNY in dividends, with 17.0163 million CNY distributed over the past three years [3].